T. Guillaume

P. Chevallier, M. Béné, P. Moreau, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

I. Yakoub-Agha, D. Blaise, P. Rohrlich, 2018, Bone Marrow Transplantation.

Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy

I. Yakoub-Agha, D. Blaise, J. Bay, 2017, Bone Marrow Transplantation.

Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas

P. Chevallier, P. Moreau, A. Moreau, 2017, Annals of Hematology.

Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience

P. Chevallier, P. Moreau, C. Leux, 2016, Annals of Hematology.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

P. Chevallier, M. Mohty, M. Béné, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

BCR‐ABL1 molecular remission after 90Y‐epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B‐ALL: proof of principle

P. Chevallier, C. Bodet-Milin, F. Kraeber-Bodéré, 2013, European journal of haematology.

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

P. Chevallier, P. Moreau, H. Avet-Loiseau, 2005, Leukemia research.

Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity.

P. Chevallier, C. Touzeau, J. Delaunay, 2008, Leukemia research.

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

P. Chevallier, M. Mohty, H. Avet-Loiseau, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

P. Chevallier, M. Béné, X. Thomas, 2015, The Lancet. Haematology.

P. Chevallier, M. Mohty, M. Béné, 2016, Seminars in hematology.

Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide

P. Chevallier, M. Béné, P. Moreau, 2020, Annals of Hematology.

Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide

P. Chevallier, M. Béné, P. Moreau, 2020, Acta oncologica.

Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipient

P. Chevallier, D. Boutolleau, P. Moreau, 2008, Haematologica.

placebo- controlled, randomized phase Ib study ovarian cancer before and after chemotherapy: a multicentric Thrombopoietic effects and toxicity of interleukin-6 in patients with

M. Berlière, Y. Humblet, V. D’Hondt, 2011 .

Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study.

M. Berlière, Y. Humblet, A. V. van Oosterom, 1995, Blood.

Retrovirus-mediated gene transfer of the human multidrug resistance-associated protein into hematopoietic cells protects mice from chemotherapy-induced leukopenia.

J. Machiels, A. Feyens, V. D’Hondt, 1999, Human gene therapy.

Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study

P. Chevallier, M. Mohty, J. Galmiche, 2014, United European gastroenterology journal.

Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study.

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2017, Blood.

Deciphering the biology of KIR2DL3+ T lymphocytes that are associated to relapse in haploidentical HSCT

P. Chevallier, C. Retière, K. Gagne, 2021, Scientific Reports.

Retroviral-mediated transfer of genes encoding interleukin-2 and interleukin-12 into fibroblasts increases host antitumor responsiveness

M. André, A. Feyens, T. Hawley, 1999, Cancer Gene Therapy.

Detection of circulating tumor by reverse transcriptase polymerase chain reaction.

J. Goeminne, T. Guillaume, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of various blood and graft sources: a prospective series

P. Chevallier, M. Mohty, M. Béné, 2013, Transfusion.

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

P. Chevallier, M. Béné, P. Moreau, 2019, Cytokine.

Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution.

D. Rubinstein, M. Symann, P. Leblanc, 1994, Cancer research.

Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults.

M. Labopin, P. Chevallier, M. Mohty, 2014, Experimental hematology.

Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT

P. Chevallier, M. Mohty, P. Moreau, 2014, Bone Marrow Transplantation.

Peripheral Blood Plasmacytoid Dendritic Cells at Day 100 Can Predict Outcome after Allogeneic Stem Cell Transplantation.

P. Chevallier, M. Mohty, M. Grégoire, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

P. Chevallier, M. Mohty, P. Moreau, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation

P. Chevallier, M. Mohty, P. Moreau, 2012, Bone Marrow Transplantation.

Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients?

P. Chevallier, M. Mohty, P. Moreau, 2012, Transplantation.

Quantification of CD34+ cells mobilized into the peripheral blood predicts the yield of the leukapheresis product and can replace progenitor assays.

Y. Humblet, M. André, A. Feyens, 1997, Cytokines, cellular & molecular therapy.

IL‐3 and Peripheral blood stem cell harvesting

V. D’Hondt, M. Symann, T. Guillaume, 1993, Stem cells.

Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.

J. Canon, Y. Humblet, V. D’Hondt, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous peripheral blood stem cell transplantation for lung cancer.

Y. Humblet, K. Zaner, D. Rubinstein, 1999, Bailliere's best practice & research. Clinical haematology.

Clearance kinetics of CD34+ cells from peripheral blood: an independent predictor of hematologic recovery after high-dose chemotherapy and hematopoietic stem cell transplantation

J. Wuu, Y. Humblet, M. André, 1999, Bone Marrow Transplantation.

The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed.

J. Canon, Y. Humblet, M. André, 1999, Leukemia & lymphoma.

Retroviral-mediated gene transfer of human multidrug resistance associated murine hematopoietic cells

J. Machiels, A. Feyens, V. D’Hondt, 1998 .

Overexpression of DNA-binding protein B gene product in breast cancer as detected by in vitro-generated combinatorial human immunoglobulin libraries.

R. Ashfaq, A. Stortchevoi, M. Boosalis, 2002, Cancer research.

Increased Th17/Treg ratio in chronic liver GVHD

P. Chevallier, M. Mohty, P. Moreau, 2014, Bone Marrow Transplantation.

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation

P. Chevallier, M. Mohty, P. Moreau, 2011, Leukemia.

Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.

P. Chevallier, M. Béné, P. Moreau, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

FLT3 ligand plasma levels in acute myeloid leukemia

P. Chevallier, M. Béné, P. Moreau, 2019, Haematologica.

FLT 3 ligand plasma levels in acute myeloid leukemia

P. Chevallier, M. Béné, P. Moreau, 2019 .

Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC

J. Bourhis, M. Labopin, P. Chevallier, 2018, Oncotarget.

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2017, Haematologica.

Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-T

P. Chevallier, M. Mohty, F. Rialland, 2016, Leukemia & lymphoma.

A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia

P. Chevallier, M. Béné, P. Moreau, 2020, Cancer medicine.

Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go?

M. Mohty, P. Moreau, T. Gastinne, 2011, Seminars in hematology.

18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study

P. Chevallier, M. Mohty, P. Moreau, 2014, Bone Marrow Transplantation.

Cytotect®CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study

I. Yakoub-Agha, S. Alain, S. Belaiche, 2018, Bone Marrow Transplantation.

Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience

P. Chevallier, P. Moreau, C. Touzeau, 2020, Bone Marrow Transplantation.

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study

P. Moreau, C. Touzeau, B. Mahé, 2019, Annals of Hematology.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study

P. Chevallier, P. Moreau, C. Touzeau, 2019, Annals of Hematology.

Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study

P. Chevallier, P. Moreau, M. Péré, 2017, Antimicrobial Agents and Chemotherapy.

Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.

P. Chevallier, M. Mohty, P. Moreau, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases

P. Chevallier, P. Moreau, C. Touzeau, 2018, Leukemia research reports.

Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients

P. Chevallier, P. Fenaux, T. Cluzeau, 2020, British journal of haematology.

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine

P. Chevallier, H. Vié, M. Béné, 2022, Vaccines.

Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience.

P. Chevallier, M. Mohty, P. Moreau, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.

C. Gisselbrecht, Y. Humblet, C. Doyen, 1992, Experimental hematology.

Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.

P. Chevallier, M. Grégoire, D. Wreschner, 2019, Experimental hematology.

Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.

P. Chevallier, P. Moreau, B. Mahé, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases

P. Chevallier, M. Mohty, H. Avet-Loiseau, 2009, Leukemia.

Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2020, Annals of Hematology.

Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation

P. Chevallier, M. Mohty, M. Béné, 2015, Annals of Hematology.

Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced‐intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo‐SCT)

P. Chevallier, M. Mohty, P. Moreau, 2013, European journal of haematology.

Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution

P. Chevallier, C. Retière, M. Béné, 2020, The Journal of Immunology.

Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia

P. Chevallier, C. Retière, M. Béné, 2020, Cancers.

Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant

P. Chevallier, M. Béné, P. Moreau, 2021, British journal of haematology.

Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

P. Chevallier, I. Yakoub-Agha, M. Mohty, 2016 .

A 4 or 5 Deauville score assessed by (18)F-FDG-PET CT early post-allotransplant is highly predictive of relapse in lymphoma patients.

P. Chevallier, M. Béné, P. Moreau, 2018 .

Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease

P. Chevallier, M. Mohty, P. Tiberghien, 2012, Leukemia.

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

H. Dombret, P. Chevallier, M. Béné, 2015, Haematologica.

Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.

P. Chevallier, M. Mohty, E. Lippert, 2012, Leukemia research.

[Multiple organ failure and disseminated adenoviral infection].

D. Villers, C. Guitton, C. Touzeau, 2010, Medecine et maladies infectieuses.

Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation

P. Chevallier, X. Saulquin, C. Retière, 2018, Oncotarget.

Impact of stem cell graft on early viral infections and immune reconstitution after allogeneic transplantation in adults.

P. Chevallier, M. Mohty, M. Rimbert, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Parvovirus B19 and blood products

C. Prowse, T. Guillaume, 1994, The Lancet.

Cemiplimab‐rwlc in advanced cutaneous squamous cell carcinoma: real‐world experience in a French dermatology department

T. Guillaume, E. Puzenat, F. Aubin, 2021, The British journal of dermatology.

Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source

P. Chevallier, M. Mohty, L. Planche, 2010, Bone Marrow Transplantation.

Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.

P. Chevallier, M. Mohty, P. Moreau, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-lasting HHV-6 reactivation in long-term adult survivors after double umbilical cord blood allogeneic stem cell transplantation.

P. Chevallier, M. Mohty, M. Rimbert, 2014, The Journal of infectious diseases.

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

P. Chevallier, M. Béné, T. Guillaume, 2021, JAMA network open.

Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy

P. Chevallier, M. Béné, P. Moreau, 2021, British journal of haematology.

Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.

P. Chevallier, M. Mohty, P. Moreau, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Pitfalls in the detection of disseminated non-hematological tumor cells.

J. Goeminne, M. Symann, T. Guillaume, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients

P. Chevallier, M. Béné, B. Dréno, 2021, Human vaccines & immunotherapeutics.

Reduced‐toxicity conditioning with fludarabine, once‐daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial

M. Labopin, P. Chevallier, D. Blaise, 2015, Cancer.

Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion.

W. Anderson, P. Cannon, C. Benedict, 1999, Human gene therapy.

Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults

P. Chevallier, M. Mohty, M. Béné, 2017, Bone Marrow Transplantation.

Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial

M. Labopin, P. Chevallier, D. Blaise, 2014, Haematologica.

Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft‐versus‐host disease

P. Chevallier, M. Mohty, J. Delaunay, 2015, Journal of leukocyte biology.

Increased plasmacytoid dendritic cells and RORγt‐expressing immune effectors in cutaneous acute graft‐versus‐host disease

P. Chevallier, M. Mohty, P. Moreau, 2013, Journal of leukocyte biology.

Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide

P. Chevallier, M. Béné, P. Moreau, 2018, Bone Marrow Transplantation.

Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide

P. Chevallier, C. Retière, M. Béné, 2019, The Journal of Immunology.

Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation

P. Chevallier, M. Béné, P. Moreau, 2016, Bone Marrow Transplantation.

Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors

P. Chevallier, M. Mohty, P. Moreau, 2009, Bone Marrow Transplantation.

Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning

P. Chevallier, D. Blaise, M. Mohty, 2013, Leukemia.

Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival.

M. Labopin, P. Chevallier, M. Mohty, 2016, Blood.

Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high risk acute myeloid leukemia or myelodysplastic syndrome.

P. Chevallier, S. Thépot, L. Planche, 2021, Transplantation and cellular therapy.

Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies

B. Esterni, P. Chevallier, D. Blaise, 2014, Haematologica.

Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.

P. Chevallier, M. Mohty, P. Moreau, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Complete Donor T-Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced Intensity Conditioning Regimen Allogeneic Transplantation in Adults

P. Chevallier, M. Mohty, P. Moreau, 2014 .

Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults.

P. Chevallier, M. Mohty, P. Moreau, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2019, Bone Marrow Transplantation.

Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.

P. Chevallier, M. Mohty, P. Moreau, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors

P. Chevallier, M. Mohty, P. Moreau, 2010, Bone Marrow Transplantation.

Fludarabine, IV Busulfan and Antithymocyte Globulins-Based Reduced-Toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation (allo-SCT): Results of a Multicenter Prospective Trial

M. Labopin, P. Chevallier, D. Blaise, 2012 .

Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens

D. Blaise, M. Mohty, P. Moreau, 2008, Bone Marrow Transplantation.

Efficacy of anti‐severe acute respiratory syndrome coronavirus 2 mRNA vaccines in adults with severe acquired aplastic anemia with or without allogeneic hematopoietic stem cell transplantation

P. Chevallier, M. Béné, T. Guillaume, 2022, EJHaem.

Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier

P. Chevallier, M. Béné, P. Moreau, 2017, Bone Marrow Transplantation.

Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells

P. Chevallier, B. Clémenceau, T. Guillaume, 2023, Biomedicines.

Restriction fragment length polymorphisms and single germline coding region sequence in VH18/2, a duplicated gene encoding autoantibody.

M. Symann, T. Guillaume, D. Rubinstein, 1993, Molecular immunology.

Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients

P. Chevallier, M. Béné, B. Clémenceau, 2022, Cells.

Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT

P. Chevallier, M. Mohty, P. Moreau, 2014, Bone Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation for T‐prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM‐TC)

I. Yakoub-Agha, D. Blaise, M. Mohty, 2015, European journal of haematology.

How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome.

P. Chevallier, A. Bazarbachi, C. Pautas, 2017, Current research in translational medicine.

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

P. Chevallier, M. Mohty, M. Béné, 2017, European journal of haematology.

Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma

M. Mohty, P. Moreau, B. Mahé, 2012, Leukemia.

Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial

P. Chevallier, D. Blaise, M. Mohty, 2015, Haematologica.

Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies

P. Chevallier, M. Béné, T. Guillaume, 2022, Bone Marrow Transplantation.

Deconditioning, fatigue and impaired quality of life in long-term survivors after allogeneic hematopoietic stem cell transplantation

P. Chevallier, P. Gourraud, A. Magnan, 2018, Bone Marrow Transplantation.

Lung Resection for Invasive Pulmonary Aspergillosis in Neutropenic Patients with Hematologic Malignancies: Long Term Results in Thirty Two Cases.

P. Moreau, C. Touzeau, J. Delaunay, 2006 .

Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma

P. Chevallier, M. Mohty, P. Moreau, 2010, Leukemia & lymphoma.

A novel complete blood count‐based score to screen for myelodysplastic syndrome in cytopenic patients

M. Boubaya, P. Chevallier, M. Béné, 2018, British journal of haematology.

Peripheral levels of monocytic myeloid‐derived suppressive cells before and after first induction predict relapse and survivals in AML patients

P. Chevallier, M. Béné, T. Guillaume, 2022, Journal of cellular and molecular medicine.

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia

H. Dombret, P. Chevallier, M. Béné, 2017, Haematologica.

Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide

P. Chevallier, M. Béné, S. Thépot, 2021, Cancer medicine.

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a Flamsa Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

P. Chevallier, M. Mohty, X. Thomas, 2011 .

Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft

P. Chevallier, M. Béné, P. Moreau, 2020, Scientific Reports.

Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies

P. Chevallier, M. Béné, P. Moreau, 2018, Oncotarget.

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

P. Chevallier, M. Rimbert, M. Béné, 2022, Transplantation and Cellular Therapy.

Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study

Elsa, P. Chevallier, M. Béné, 2021 .

Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.

P. Chevallier, M. Béné, P. Moreau, 2020, Haematologica.

Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France

P. Chevallier, M. Béné, T. Guillaume, 2022, JAMA network open.

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant

P. Chevallier, H. Vié, M. Béné, 2022, EJHaem.

Persistence of CD33 expression at relapse in CD33+ acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease

P. Chevallier, M. Mohty, H. Avet-Loiseau, 2008, British journal of haematology.

Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients

P. Chevallier, M. Béné, T. Guillaume, 2022, Hematological oncology.

Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study.

H. Dombret, M. Bernard, P. Chevallier, 2011, Blood.

HHV-6 cell receptor CD46 expression on various cell subsets of six blood and graft sources: a prospective series.

P. Chevallier, M. Mohty, M. Béné, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Molecular analysis of a germ line-encoded idiotypic marker of pathogenic human lupus autoantibodies.

R. Schwartz, F. Young, T. Logtenberg, 1990, Journal of immunology.

Individual VH genes detected with oligonucleotide probes from the complementarity-determining regions.

R. Schwartz, F. Young, T. Logtenberg, 1990, Journal of immunology.

Ptcy + ATG Vs Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Haplo-Transplants: Comparison of NK and T Cell Effector Reconstitution

P. Chevallier, C. Retière, M. Béné, 2019, Blood.

Safety and efficacy of rituximab in steroid-refractory chronic GVHD

P. Chevallier, M. Mohty, P. Moreau, 2013, Bone Marrow Transplantation.

HLA-A, -B, -C and –DRB1 High Resolution Matching Can Improve Patient' Outcome After Double Umbilical Allogeneic Stem Cell Transplantation (allo-SCT)

P. Chevallier, M. Mohty, P. Moreau, 2013 .

Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report

P. Chevallier, M. Béné, T. Guillaume, 2022, Acta Haematologica.

Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life

P. Chevallier, P. Moreau, C. Leux, 2020, Annals of Hematology.

Reply to K. Filanovsky et al

P. Chevallier, M. Mohty, H. Avet-Loiseau, 2010 .

Tolerance and Effectiveness of Combined Il-3 and G-csf in Collecting Peripheral-blood Progenitor Cells (pbpc) Following Disease-oriented Chemotherapy

Y. Humblet, V. D’Hondt, C. Doyen, 1993 .

Addition of ATG to non-myeloablative peripheral blood haploidentical transplant with PTCY decreases acute GVHD rates and improves GVHD-relapse free survival

P. Chevallier, M. Béné, T. Guillaume, 2023, Bone Marrow Transplantation.

[Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].

I. Yakoub-Agha, M. Michallet, T. Guillaume, 2019, Bulletin du cancer.

[Donor Lymphocyte Infusions (DLI): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

I. Yakoub-Agha, J. de Vos, J. Bay, 2018, Bulletin du cancer.

[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].

P. Chevallier, I. Yakoub-Agha, A. Bazarbachi, 2017, Bulletin du cancer.

Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study.

Y. Humblet, A. Feyens, V. D’Hondt, 1994, Bone marrow transplantation.

Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients

P. Moreau, F. Kraeber-Bodéré, J. Barbet, 2012, Tumor Biology.

ESTIC position paper: high-dose chemotherapy for breast cancer, investigation should continue.

B. Coiffier, L. Kanz, J. Crown, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Anti-CD34+ Fabs generated against hematopoietic stem cells in HIV-derived combinatorial immunoglobulin library suggest antigen-selected autoantibodies.

M. Boosalis, D. Rubinstein, P. Leblanc, 1998, Molecular immunology.

Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseases

P. Chevallier, M. Mohty, P. Moreau, 2016, Bone Marrow Transplantation.

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients

P. Chevallier, M. Béné, P. Moreau, 2021, EJHaem.

Sequential Regimen of Clofarabine, Cytarabine and Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in Primary Treatment Failure

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2014 .

Addition of ATG to Clofarabine-Based Reduced Intensity Conditioning Regimen with PBSC and Ptcy in Adults with Myeloid Malignancies

P. Chevallier, M. Béné, T. Guillaume, 2022, Blood.

Germline complexity, restriction fragment length polymorphism, and coding region sequences of the human VH7 gene family identified with family-specific FR3 segment oligonucleotides.

P. Leblanc, T. Guillaume, R. Schwartz, 1994, Molecular immunology.

FDG-PET/CT for the detection of gastrointestinal graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

P. Chevallier, M. Mohty, C. Bodet-Milin, 2011 .

Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study.

I. Yakoub-Agha, A. Nagler, M. Mohty, 2008 .

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

H. Dombret, P. Chevallier, M. Béné, 2015, Haematologica.

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2017, Haematologica.

Increased plasmacytoid dendritic cells and RORγt‐expressing immune effectors in cutaneous acute graft‐versus‐host disease

P. Chevallier, M. Mohty, P. Moreau, 2013, Journal of leukocyte biology.

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

P. Chevallier, S. Thépot, T. Guillaume, 2019, Blood.

Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.

P. Chevallier, C. Touzeau, B. Mahé, 2024, American journal of hematology.

Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial

P. Chevallier, L. Planche, T. Guillaume, 2023, EClinicalMedicine.

Post‐transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced‐intensity conditioning allotransplant

P. Chevallier, M. Béné, T. Guillaume, 2023, Clinical and translational medicine.

Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial

M. Labopin, D. Blaise, M. Mohty, 2024, Blood cancer journal.